The Transitions Project: Efficacy Trial
- Conditions
- Lung Cancer
- Registration Number
- NCT05087251
- Lead Sponsor
- Massachusetts General Hospital
- Brief Summary
The aim of this study is to evaluate the efficacy of a brief psychoeducational intervention to improve quality of life in patients with lung cancer who are transitioning from active treatment to surveillance.
- Detailed Description
This is a randomized controlled trial to test the efficacy of a brief psychoeducational intervention relative to a control condition for improving quality of life in patients with lung cancer who are transitioning from treatment to surveillance.
In this study, participants will complete survey questions and will be randomly assigned to receive a 5-session program or a 1-session program.
It is expected that about 100 people will take part in this research study.
The American Lung Association is supporting this research by providing funding for the research study.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 100
-
Age 21 or older
-
Able to read and respond in English
-
Diagnosis of non-small cell lung cancer or small cell lung cancer
-
Documented curative treatment plan including systemic therapy +/- radiation and +/- surgery
-
Completed cancer treatment within past 3 weeks
- If final treatment is systemic therapy +/- radiation: within 3 weeks after cancer care team determination that treatment is complete
- If final treatment is surgery: within 3 weeks after hospital discharge following surgery
- Comorbid health condition that would interfere with study participation
- Current participation in cognitive behavioral therapy treatment
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Quality of life: Functional Assessment of Cancer Therapy-Lung Cancer Up to 12 weeks We will investigate longitudinal differences in quality of life between study groups (Functional Assessment of Cancer Therapy-Lung Cancer score range 0-144, with higher scores indicating better quality of life)
- Secondary Outcome Measures
Name Time Method Fear of cancer recurrence: Fear of Cancer Recurrence Scale 7 Up to 12 weeks We will investigate longitudinal differences in fear of cancer recurrence between study groups (Fear of Cancer Recurrence Scale 7, score range 7-35, with higher scores indicating more fear of cancer recurrence)
Symptom burden: Edmonton Symptom Assessment Scale Up to 12 weeks We will investigate longitudinal differences in symptom burden (Edmonton Symptom Assessment Scale score range 0-90, with higher scores indicating more symptom burden)
Psychological symptom burden: Hospital Anxiety and Depression Scale Up to 12 weeks We will investigate longitudinal differences in psychological symptom burden (Hospital Anxiety and Depression Scale score range 0-42 with higher scores indicating more psychological symptom burden)
Social support: Multidimensional Scale of Perceived Social Support Up to 12 weeks We will investigate longitudinal differencs in social support (Multidimensional Scale of Perceived Social Support score range 12-84, with higher scores indicating more social support)
Social isolaton: Campaign to End Loneliness Measurement Tool Up to 12 weeks We will investigate longitudinal differences in social isolation (Campaign to End Loneliness measurement tool score range 0-12 with higher scores indicating more social isolation)
Trial Locations
- Locations (2)
Massachusetts General Hospital Cancer Center
🇺🇸Boston, Massachusetts, United States
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Massachusetts General Hospital Cancer Center🇺🇸Boston, Massachusetts, United StatesLara Traeger, PhDPrincipal Investigator